STOCK TITAN

Mineralys (MLYS) CMO exercises options and sells 20,406 shares in 10b5-1 trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom reported option exercises and share sales in the company’s stock. On April 13, he exercised stock options covering a total of 14,058 shares of Common Stock at strike prices of $1.08, $10.20, and $14.25 per share. That same day, he conducted an open-market sale of 14,058 shares of Common Stock at a weighted-average price of $26.5391 per share. On April 15, he completed a second open-market sale of 6,348 shares at $27.66 per share under a Rule 10b5-1 trading plan. After these transactions, he directly holds 69,792 shares of Common Stock.

Positive

  • None.

Negative

  • None.
Insider Rodman David Malcom
Role Chief Medical Officer
Sold 20,406 shs ($549K)
Type Security Shares Price Value
Sale Common Stock 6,348 $27.66 $176K
Exercise Stock Option 6,349 $0.00 --
Exercise Stock Option 3,542 $0.00 --
Exercise Stock Option 4,167 $0.00 --
Exercise Common Stock 6,349 $1.08 $7K
Exercise Common Stock 3,542 $10.20 $36K
Exercise Common Stock 4,167 $14.25 $59K
Sale Common Stock 14,058 $26.5391 $373K
Holdings After Transaction: Common Stock — 69,792 shares (Direct); Stock Option — 19,046 shares (Direct)
Footnotes (1)
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.3676 to $26.8400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
Total shares sold 20,406 shares Net shares sold across reported open-market transactions
First sale price $26.5391 per share Weighted-average price for 14,058-share sale on April 13
Second sale price $27.66 per share Price for 6,348-share open-market sale on April 15
Options exercised 14,058 shares Total Common Stock from option exercises on April 13
Strike price 1 $1.08 per share Exercise price for 6,349-option tranche
Strike price 2 $10.20 per share Exercise price for 3,542-option tranche
Strike price 3 $14.25 per share Exercise price for 4,167-option tranche
Shares held after 69,792 shares Direct Common Stock holdings after transactions
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported in Column 4 is a weighted-average price."
stock option financial
"The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rodman David Malcom

(Last)(First)(Middle)
150 N. RADNOR CHESTER RD.
SUITE F200

(Street)
RADNOR PENNSYLVANIA 19087

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/13/2026M(1)6,349A$1.0882,489D
Common Stock04/13/2026M(1)3,542A$10.286,031D
Common Stock04/13/2026M(1)4,167A$14.2590,198D
Common Stock04/13/2026S(1)14,058D$26.5391(2)76,140D
Common Stock04/15/2026S(1)6,348D$27.6669,792D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$1.0804/13/2026M(1)6,349 (3)07/11/2032Common Stock6,349$019,046D
Stock Option$10.204/13/2026M(1)3,542 (4)02/13/2035Common Stock3,542$0120,417D
Stock Option$14.2504/13/2026M(1)4,167 (3)02/13/2034Common Stock4,167$091,667D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.3676 to $26.8400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
4. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
Remarks:
/s/ Adam Levy, Attorney-in-fact04/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)